Ozempic 'mistakes' claims: what the evidence actually says

What's this video probably claiming?

Based on the caption, @joaquinpuermaendocrino is likely arguing that Ozempic failures are not the drug's fault but rather the result of poor strategy and inadequate medical supervision. The three "common mistakes" framing is a popular content structure in the GLP-1 space, and the mention of "rebounds" suggests the video probably addresses weight regain after stopping semaglutide. The creator appears to position structured clinical guidance as the solution, which is a reasonable premise on its face. The comment-bait mechanic ("comment GUÍA") is standard lead-generation for DM funnels, which raises questions about what kind of guidance is actually being offered and whether it constitutes regulated medical advice. Worth watching closely: whether the "strategy" being sold is evidence-based titration and behavioral support, or a proprietary protocol dressed up in clinical language.

What does the science actually show?

The rebound concern is real and well-documented. The STEP 1 trial extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism) found that participants who discontinued semaglutide 2.4 mg regained approximately two-thirds of their lost weight within one year. That is not a drug failure in isolation. It reflects what happens when a chronic disease medication is stopped without a maintenance plan. On the supervision question, a 2023 analysis in JAMA Internal Medicine (Ghassemi et al.) found significant variability in GLP-1 prescribing practices in telehealth settings, with many patients receiving minimal follow-up. So the creator's core thesis that lack of strategy and monitoring causes problems has legitimate clinical support. The issue is whether a TikTok DM funnel constitutes adequate follow-up, and the answer to that is almost certainly no.

Where does the social media noise diverge from clinical reality?

The framing of "mistakes" individualizes what is largely a systemic problem. Obesity medicine specialists will tell you that semaglutide works as part of a broader treatment plan including dietary modification, behavioral support, and realistic long-term expectations. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed sustained weight loss of around 15.2% over 104 weeks with continuous use, but that requires ongoing access, cost management, and tolerance of side effects, none of which a three-mistake framework captures. Social media GLP-1 content also tends to skip over the gastrointestinal adverse event profile. Around 44% of participants in STEP 1 reported nausea, and roughly 20% had vomiting. These are not minor details. They affect adherence and need clinical management, not a comment-section guide.

What should you actually know?

If you are using or considering semaglutide, a few things matter more than any three-point social media framework. First, weight regain after stopping is not a personal failure. It is a documented pharmacological reality that reflects the chronic nature of obesity. Second, titration schedules exist for a reason. Moving through doses too quickly is a genuine cause of side-effect-driven discontinuation, and that decision should involve a prescriber, not a DM conversation with an influencer. Third, "strategy" in clinical terms means integrating GLP-1 therapy with dietary counseling and behavioral support, not a proprietary protocol. A 2021 meta-analysis in Obesity Reviews (Wadden et al.) found that combining lifestyle intervention with pharmacotherapy produced meaningfully better outcomes than either alone. The creator's general point about supervision has merit. The delivery mechanism is the part worth scrutinizing.